Public Can’t Choose Vaccine Brand Says Roque Amid Sinovac Criticism

Public Can’t Choose Vaccine Brand They Want Asserts Roque

PUBLIC CAN’T CHOOSE VACCINE BRAND – Recently, Netizens were outraged that the government procured 25 million doses of China’s Sinovac vaccine.

Based on previous reports, the Sinovac vaccine was found to be 50% effective against COVID-19. However, the DOH emphasized that 50% is still the minimum requirement of a vaccine candidate.

Along with this, the government’s vaccine czar, Carlito Galvez Jr. long emphasized that the Philippines planned to prioritize Sinovac or Sinopharm in the first quarter of 2021. Meanwhile, because of this announcement, #Sinovac trended on Twitter.

Public Can't Choose Vaccine Brand Says Roque Amid Sinovac Criticism
Image from: RTV Malacañang

Netizens complained why the government was adamant to get the Sinovac vaccine when Local Government Units were able to get a deal on cheaper more effective vaccines against COVID-19. Amid the criticism, Presidential Spokesperson Harry Roque said the Filipino people shouldn’t be “picky”.

According to an article from Inquirer, Roque said:

Totoo po, meron tayong lahat na karapatan para sa mabuting kalusugan pero hindi naman po pwede na pihikan dahil napakaraming Pilipino na dapat turukan

Wala pong pilian, wala kasing pilitan. Pero magsa-sign ka ng waiver na hindi ka nagpaturok at kapag ikaw ay may prayoridad, siyempre mawawala ang prayoridad mo, sasama ka sa the rest ng taumbayan na naghihintay ng bakuna

Currently, the Philippines managed to secure 2.6 million doses of AstraZeneca’s vaccine. Furthermore a deal for 30 million doses of the Covovax vaccine was also secured.

Meanwhile, Health Secretary Francisco Duque announced that the Philippines also got 25 million doses of China’s Sinovac vaccine expected to arrive next month.

Thanks for reading. We aim to provide our readers with the freshest and most in-demand content. Come back next time for the latest news here on Philnews.

READ ALSO: Choosing Sinovac Is Nonsense Due To 50% Efficacy Says Solon

Leave a Comment